Payment overview · 2025
General Payments
$3,664.35
171 reported records · 24 companies
Healthcare provider profile · identity verified
Gregory Papa, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · NEW CASTLE, DE · NPI 1730242397
Verified facts
What the public records show
CMS Open Payments records show Gregory Papa, D.O. received $3,664.35 in general payments during 2025 across 171 reported records.
AstraZeneca Pharmaceuticals LP accounted for 15.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 40 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 143 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $570.36 | 15.6% | 11 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $472.42 | 12.9% | 28 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $426.64 | 11.6% | 20 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $405.43 | 11.1% | 15 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $341.39 | 9.3% | 28 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $311.84 | 8.5% | 16 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $275.03 | 7.5% | 12 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $151.09 | 4.1% | 7 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $133.33 | 3.6% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $75.90 | 2.1% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $72.14 | 2.0% | 4 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $68.33 | 1.9% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $61.55 | 1.7% | 3 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $44.71 | 1.2% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $41.25 | 1.1% | 1 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $38.35 | 1.1% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $37.64 | 1.0% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $31.71 | 0.9% | 2 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $28.74 | 0.8% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.11 | 0.5% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $16.32 | 0.5% | 1 | 2025 |
| EVOKE PHARMA, INC. | Unresolved — no canonical attribution shown | $16.19 | 0.4% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $15.25 | 0.4% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $9.63 | 0.3% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,664.35 | 171 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $394.93 | 19 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $389.52 | 7 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $349.98 | 17 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $335.69 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $325.54 | 12 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $325.54 | 12 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $311.84 | 16 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $286.17 | 23 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $279.93 | 24 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $188.85 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $186.25 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $178.10 | 10 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $148.99 | 7 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $134.13 | 16 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $133.33 | 1 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $130.29 | 6 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $96.93 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $91.62 | 5 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $68.33 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $61.55 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $56.42 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $56.42 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $48.53 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $44.71 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $41.25 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $40.61 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $40.61 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $40.61 | 3 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $38.35 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $37.64 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $31.71 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $31.71 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $31.71 | 1 | 2025 |
Source payment records
|
|||||
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $28.74 | 2 | 2025 |
Source payment records
|
|||||
| VIVITROL Normalized: vivitrol |
Drug | Alkermes, Inc. | $20.80 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $19.11 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $16.32 | 1 | 2025 |
Source payment records
|
|||||
| GIMOTI Normalized: gimoti |
Drug | EVOKE PHARMA, INC. | $16.19 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $15.25 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $9.63 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 64 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 108 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 52 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 143 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 77 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
108 | 19 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
52 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
77 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
52 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
143 | 24 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
64 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Losartan Potassium | Losartan Potassium | 436 | 122 |
| Amlodipine Besylate | Amlodipine Besylate | 434 | 114 |
| Alprazolam | Alprazolam | 349 | 57 |
| Gabapentin | Gabapentin | 316 | 73 |
| Omeprazole | Omeprazole | 313 | 77 |
| Oxycodone Hcl | Oxycodone Hcl | 313 | 46 |
| Levothyroxine Sodium | Levothyroxine Sodium | 255 | 62 |
| Atorvastatin Calcium | Atorvastatin Calcium | 252 | 72 |
| Metoprolol Succinate | Metoprolol Succinate | 249 | 59 |
| Pravastatin Sodium | Pravastatin Sodium | 249 | 67 |
| Prednisone | Prednisone | 204 | 91 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 178 | 43 |
| Metformin Hcl | Metformin Hcl | 176 | 42 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 165 | 42 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 163 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 147 | 36 |
| Ozempic | Semaglutide | 143 | 24 |
| Ibuprofen | Ibuprofen | 140 | 40 |
| Azithromycin | Azithromycin | 118 | 65 |
| Lisinopril | Lisinopril | 113 | 31 |
| Furosemide | Furosemide | 111 | 32 |
| Clonazepam | Clonazepam | 110 | 19 |
| Farxiga | Dapagliflozin Propanediol | 108 | 19 |
| Glimepiride | Glimepiride | 107 | 28 |
| Bupropion Xl | Bupropion Hcl | 104 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 101 | 27 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 95 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 91 | 74 |
| Trazodone Hcl | Trazodone Hcl | 88 | 16 |
| Metformin Hcl Er | Metformin Hcl | 87 | 26 |
| Montelukast Sodium | Montelukast Sodium | 87 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 86 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 82 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 77 | 18 |
| Sertraline Hcl | Sertraline Hcl | 77 | 23 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 77 | 15 |
| Lorazepam | Lorazepam | 75 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 70 | 33 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 68 | 54 |
| Carvedilol | Carvedilol | 68 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 68 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 67 | 21 |
| Eliquis | Apixaban | 64 | 16 |
| Meloxicam | Meloxicam | 64 | 16 |
| Tramadol Hcl | Tramadol Hcl | 63 | 11 |
| Pantoprazole Sodium | Pantoprazole Sodium | 61 | 15 |
| Pregabalin | Pregabalin | 61 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 61 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 58 | 14 |
| Diazepam | Diazepam | 57 | 19 |
| Buspirone Hcl | Buspirone Hcl | 55 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 54 | 35 |
| Jardiance | Empagliflozin | 52 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 50 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 49 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 48 | suppressed |
| Baclofen | Baclofen | 47 | 11 |
| Ondansetron Odt | Ondansetron | 47 | 17 |
| Famotidine | Famotidine | 45 | suppressed |
| Olanzapine | Olanzapine | 45 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 44 | suppressed |
| Myrbetriq | Mirabegron | 41 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 41 | 11 |
| Xarelto | Rivaroxaban | 40 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 39 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 38 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 37 | suppressed |
| Allopurinol | Allopurinol | 36 | suppressed |
| Cephalexin | Cephalexin | 36 | 28 |
| Bupropion Hcl Sr | Bupropion Hcl | 35 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 35 | 16 |
| Morphine Sulfate Er | Morphine Sulfate | 35 | suppressed |
| Potassium Chloride | Potassium Chloride | 35 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 34 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 34 | 19 |
| Aripiprazole | Aripiprazole | 33 | 11 |
| Simvastatin | Simvastatin | 33 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 33 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 31 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 31 | suppressed |
| Ketoconazole | Ketoconazole | 31 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 30 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 29 | suppressed |
| Spironolactone | Spironolactone | 29 | suppressed |
| Atenolol | Atenolol | 28 | suppressed |
| Mounjaro | Tirzepatide | 28 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | suppressed |
| Metolazone | Metolazone | 26 | suppressed |
| Trulicity | Dulaglutide | 26 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 25 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 25 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 24 | suppressed |
| Penicillin V Potassium | Penicillin V Potassium | 23 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 17 |
| Tresiba Flextouch U-100 | Insulin Degludec | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Ezetimibe | Ezetimibe | 20 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 19 | suppressed |
| Methylprednisolone | Methylprednisolone | 19 | 15 |
| Celecoxib | Celecoxib | 18 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Finasteride | Finasteride | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | 11 |
| Rybelsus | Semaglutide | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | suppressed |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 14 | suppressed |
| Phenobarbital | Phenobarbital | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Hysingla Er | Hydrocodone Bitartrate | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Methadone Hcl | Methadone Hcl | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Minoxidil | Minoxidil | 12 | suppressed |
| Niacin Er | Niacin | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,664.35 · 171 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, AREXVY, Auvelity, BREZTRI, BRIXADI, CAPLYTA, COMIRNATY, Dexcom G6 Transmitter, ELIQUIS, FANAPT, FARXIGA, GIMOTI, IBSRELA, INGREZZA, JARDIANCE, Korlym, LYBALVI, MOUNJARO, NURTEC ODT, OTEZLA, Omnipod, Ozempic, PREVNAR 20, QULIPTA, REPATHA, Rybelsus, SUBLOCADE, Sunosi, TRELEGY ELLIPTA, UBRELVY, VIVITROL, VOQUEZNA, VRAYLAR, Veozah, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND, ZORYVE | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error